Synonyms: Example-6 [WO2020148619A1] | ZY-IL1 | ZYIL-1 | ZYIL1
Compound class:
Synthetic organic
Comment: Usnoflast (ZYIL1) is a novel oral non-steroidal anti-inflammatory compound that acts as a NLRP3 inhibitor [2-3].
|
|
References |
1. Hissaria P, Kansagra K, Patel H, Momin T, Ghoghari A, Patel H, Sharma B. (2024)
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZY-IL1 in Three Patients with Cryopyrin-Associated Periodic Syndromes. Clin Pharmacol Drug Dev, 13 (2): 152-159. [PMID:37577847] |
2. Parmar DV, Kansagra KA, Momin T, Patel HB, Jansari GA, Bhavsar J, Shah C, Patel JM, Ghoghari A, Barot A et al.. (2023)
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral NLRP3 Inflammasome Inhibitor ZYIL1: First-in-Human Phase 1 Studies (Single Ascending Dose and Multiple Ascending Dose). Clin Pharmacol Drug Dev, 12 (2): 202-211. [PMID:36065092] |
3. Sharma R, Agarwal. (2020)
Novel substituted sulfonylurea derivatives. Patent number: WO2020148619A1. Assignee: Cadila Healthcare Limited. Priority date: 13/01/2020. Publication date: 23/07/2020. |